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Introduction
Ichthyosis is a heterogeneous cluster of keratinization
disorders.1 Autosomal dominant ichthyosis vulgaris, the most
common type, has an estimated incidence of 1 in 250 births,
and X-linked recessive ichthyosis, the second most common
form, has an incidence of 1 in 6000 male births.2 In addi-
tion, there are approximately 6.7 in 100,000 cases of
moderate-to-severe ichthyosis.3 Congenital ichthyoses are
caused by mutations in the genes responsible for keratinocyte
differentiation and skin barrier function. To date, there are
36 known forms of inherited ichthyoses, with over 25 genes
being implicated and multiple mutations for each gene.4 In
ichthyosis vulgaris, mutation of the filaggrin gene leads to
a paucity or absence of the granular layer of the epidermis.5
This results in abnormal epidermal hyperplasia with ex-
cessive formation of stratum corneum, accompanied by
abnormal desquamation. The main clinical feature of this
disease is dry and rough skin with marked scaling but
without inflammation.6 The skin of the abdomen and ex-
tensor surfaces is the most commonly affected, but the skin
of the face and flexor surfaces is often spared.4
There is limited data on how patients with ichthyosis
tolerate radiation therapy.7 Here we describe a case of a
patient with congenital ichthyosis who underwent a course
of radiation therapy concurrently with chemotherapy for
treatment of squamous cell cancer of the skin.
Case report
The patient is a 51-year-old white man with congeni-
tal ichthyosis. To our knowledge, the patient has not been
formally genotyped. However, his family history, which in-
cludes his mother and sister (his only sibling) being affected
by the same disorder, is consistent with an autosomal domi-
nant ichthyosis vulgaris. The patient presented to his primary
care physician with a small, painless, pink lesion located
on the left knee. The lesion was initially treated with topical
antifungal medications for approximately 12 months. Over
the next 3 months, the patient noticed that the lesion began
to grow rapidly and to become painful. A shave biopsy of
the lesion was positive for moderately differentiated squa-
mous cell carcinoma. The patient was subsequently referred
to our institution for further management.
On physical examination, a 9-cm exophytic, malodor-
ous, ulcerated, and necrotic lesion was observed in the
anteromedial aspect of the left proximal tibia (Fig 1). The
lesion also encompassed the anterior and medial aspect of
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the proximal tibia and knee joint. There was no exposed
bone or tendon. Neuromuscular and sensory functions in
his left lower extremity were intact.
Magnetic resonance imaging (MRI) with intravenous
contrast demonstrated an 8.3 × 1.4 × 4.9 cm mass super-
ficial to the patella and patellar tendon, without evidence
of bone involvement. A fluorodeoxyglucose positron emis-
sion tomography–computed tomography scan demonstrated
a hypermetabolic (maximum standardized uptake value of
12.3) mass within the skin overlying the left knee and a
mildly enhancing (maximum standardized uptake value of
2.3) left inguinal lymph node. Biopsy of this lymph node
was negative for malignancy. This case was discussed at
our multidisciplinary tumor board, and it was determined
that an adequate resection of this lesion was not possible
short of an above-the-knee amputation. Consensus was
reached for concurrent chemoradiation to the lesion.
The patient was simulated supine on a Phillips Ingenu-
ity CT scanner (Phillips, Cleveland, OH) with a Vac-Loc
(CIVCO Radiotherapy, Coralville, IA) for immobiliza-
tion. Both legs were slightly frog-legged (ie, both thighs
slightly abducted and externally rotated), and the left knee
was raised slightly higher than the right, using a small sty-
rofoam square under the Vac-Loc (Fig 1).
Diagnostic images were fused to the simulation CT
dataset to facilitate target definition. As seen on Figure 2,
the gross tumor volume consisted of the tumor as seen in
the simulation and diagnostic images. To account for sub-
clinical disease, a clinical target volume was defined as the
gross tumor volume with a 1-cm expansion, excluding bone
and air. A 5-mm margin was added to the clinical target
volume to create the planning target volume.
Treatments were delivered with opposed lateral 6 MV
photon beams on a Varian 21EX linear accelerator in ac-
cordance with the 3-dimensional plan (Varian Eclipse
Treatment Planning System, Varian, Palo Alto, CA). Thirty-
degree dynamic wedges were deployed for dose
homogeneity. A 0.5-cm bolus (Superflab, CIVCO
Figure 1 Left knee at presentation.
Figure 2 A representative axial image from the radiation treatment plan (gross tumor volume in red; clinical target volume in yellow;
planning target volume in orange; 54.0 Gy in dark blue; 48.6 Gy in green; and Bolus in blue).
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Radiotherapy) was placed on the skin. The plan resulted
in 95% of the planning target volume receiving at least 96%
of the prescribed dose.
The patient received a daily dose of 1.8 Gy, 5 days per
week, to a total dose of 54 Gy. The patient received 7 doses
of weekly intravenous cisplatin at 40 mg/m2, 6 doses con-
currently with the radiation therapy, and the seventh dose
administered 3 days after completion of radiation therapy.
The patient tolerated this course of treatment well and did
not require any treatment breaks or dose reduction. At the
end of treatment, the patient reported decreased pain and
increased movement of this left knee joint. Not surpris-
ingly, the patient developed very limited areas of dry
desquamation (Fig 3), consistent with acute grade 1 skin
toxicity, based on the Radiation Therapy Oncology Group
acute toxicity criteria.8
The patient returned to our clinic 1 month after comple-
tion of treatment and demonstrated near-complete resolution
of the skin erythema and desquamation (Fig 4) and near-
complete resolution of the superficial knee pain.
The patient returned to our clinic again 3 months after
completion of therapy with a repeat MRI showing no evi-
dence of tumor recurrence. Incidentally, this scan
demonstrated an asymptomatic, nondepressed, subchon-
dral fracture at the inferior-lateral femoral trochlea and an
anterior, weight-bearing, lateral femoral condyle fracture.
On physical examination, the patient was asymptomatic with
a full range of motion of the left knee.
At the 6-month follow-up, the patient continued to have
very mild pain in the skin overlying the left knee that did
not require analgesic medications. There was no visible or
palpable tumor at the site of the treatment (Fig 5). An MRI
at that time did not show evidence of disease progression
and showed resolution of the imaging findings previously
interpreted as subchondral femoral fractures.
Unfortunately, 1 year after completion of therapy, the
patient presented with a rapidly enlarging, nontender, left
inguinal lymph node and ulceration at the site of the origi-
nal tumor (Fig 6). An MRI demonstrated a necrotic left groin
mass with peripheral enhancement that measured
40 × 32 × 46 mm. A fine-needle aspiration of the left in-
guinal lymph node was consistent with metastatic squamous
cell carcinoma. The patient is currently receiving salvage
therapy consisting of intravenous pembrolizumab 200 mg
every 21 days.
Discussion
We report the case of a patient with congenital ichthyo-
sis who was treated with external beam radiation therapy
concurrently with cisplatin for a large cutaneous squa-
mous cell cancer in the left knee.
The true incidence of skin cancers among patients with
ichthyosis is unknown. However, we have found a few case
reports that suggest an increased risk of skin malignan-
cies in patients with various forms of ichthyoses.9-12
Figure 3 Left knee at the end of treatment.
Figure 4 Left knee at 1-month follow-up.
Figure 5 Left knee at 6-month follow-up.
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According to the National Comprehensive Cancer Network
Guidelines for Squamous Cell Skin Cancer (Version 1.2017,
October 3, 2016), radiation therapy is contraindicated in
patients with genetic conditions predisposing to skin cancer
(including basal cell nevus syndrome and xeroderma
pigmentosum) and connective tissue diseases, including
scleroderma. However, this list does not include ichthyo-
sis. Furthermore, we were unable to find any published
reports on patients with ichthyosis who received radia-
tion therapy concurrently with chemotherapy.
As far as we know, there is a lack of prospective ran-
domized trials to evaluate the advantage of adding
chemotherapy to radiation therapy for treatment of ad-
vanced skin cancers. However, we are aware of retrospective
reports of small cohorts of patients with advanced cutane-
ous squamous cell carcinomas of the head and neck region
that show the feasibility of concurrent chemoradiation.13,14
Another retrospective report suggests the additive benefit
of platinum-based agents but not of taxanes or cetuximab
to radiation therapy in the treatment of advanced squa-
mous cell carcinomas of the skin.15 Recently, a small,
prospective, phase 2 study of a cohort of 21 patients with
advanced cutaneous squamous cell carcinomas of the head
and neck (14 of them stage 4) who received 66 to 74 Gy
concurrently with weekly cisplatin or carboplatin showed
a 1-year disease-free survival rate of approximately 50%.16
There is a profound lack of literature regarding how pa-
tients with ichthyosis tolerate radiation therapy with or
without chemotherapy, except for a case report describ-
ing the development of subcutaneous calcifications in a
patient with ichthyosis who received 41 Gy in 10 frac-
tions to the mediastinum.7 In fact, there is a lack of objective
data to predict the acute and long-term side effects of a
typical definitive dose (up to 70 Gy) in a patient with ich-
thyosis, especially concurrently with cisplatin. Frankly, we
were concerned that this patient would not be able to tol-
erate a conventional course of concurrent chemoradiation;
therefore, we chose a slightly lower dose of 54 Gy, a dose
that is typically used to treat smaller skin cancers, to ensure
patient safety. In retrospect, the dose selected may have been
too low to achieve durable local control of an advanced
lesion such as this.
Conclusion
To our knowledge, this is the first case report of a patient
with congenital ichthyosis who received radiation therapy
concurrently with chemotherapy. The patient initially had
an excellent treatment response to concurrent
chemoradiation, with minimal toxicity. The patient had an
uneventful recovery from the side effects. Our case indi-
cates that this regimen can safely be utilized in the treatment
of squamous cell carcinoma of the skin arising in patients
with congenital ichthyosis. However, additional follow-
up may be warranted for our appreciation of long-term side
effects of this regimen.
Unfortunately, the patient experienced a recurrence both
locally and regionally after 1 year. In light of this recur-
rence, and because the patient tolerated this regimen well,
a higher dose of radiation to the primary as well as elec-
tive nodal irradiations to the regions at risk could be
considered, with caution, in this patient population.
In summary, we report here that a patient with congeni-
tal ichthyosis and advanced squamous cell carcinoma of
the skin can tolerate a course of radiation therapy up to
54 Gy concurrently with cisplatin. The treatment resulted
in disease control at the site of the primary for approxi-
mately 1 year.
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